Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer
Abstract High expression of immune checkpoint molecule B7-H3 (CD276) in many cancer types makes it a promising immunotherapeutic target. Both coinhibitory and costimulatory effects of B7-H3 in tumors have been demonstrated, but the mechanism of B7-H3 immune response under dual effects is open to que...
Saved in:
| Main Authors: | Qi Shen, Kaichen Zhou, Haosen Lu, Jielin Zhang, Qiqing Xu, Chengsi Zhang, Chunhua Yang, Lijun Mao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2024-12-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-024-01674-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
B7-H3 in glioblastoma and beyond: significance and therapeutic strategies
by: Davor Babič, et al.
Published: (2024-11-01) -
B7-H3 in Cancer Immunotherapy—Prospects and Challenges: A Review of the Literature
by: Sylwia Mielcarska, et al.
Published: (2025-08-01) -
B7H3 in Gastrointestinal Tumors: Role in Immune Modulation and Cancer Progression: A Review of the Literature
by: Sylwia Mielcarska, et al.
Published: (2025-04-01) -
Tumor Immunotherapy Targeting B7-H3: From Mechanisms to Clinical Applications
by: Guo Y, et al.
Published: (2025-03-01) -
From tumor immunity to precision medicine: the next step in B7-H3/CD276 research
by: Fang Haolie, et al.
Published: (2025-03-01)